Synopsis Type 2 diabetes and Nonalcoholic fatty liver disease (NAFLD) often coexist. In patients with NAFLD, the presence of type 2 diabetes is a risk factor which can progress to nonalcoholic steatohepatitis (NASH), a severe form of NAFLD that can further develop and lead to liver fibrosis, cirrhosis, and hepatocellular cancer. Empagliflozin is an effective oral antidiabetic agent that inhibits the sodium–glucose cotransporter 2 (SGLT-2).
Inhibition of this SGLT-2 transporter promotes urinary glucose excretion, which further decreases glucose blood levels and improves insulin resistance in T2DM patients. The present study aimed at analyzing the effect of Empagliflozin on liver fat in T2DM patients and nonalcoholic Fatty Liver Disease (NAFLD) patients. This week’s “ MED FACT ” discusses the clinical trial from Diabetes Care Journal, “ Effect of Empagliflozin on Liver Fat in Patients…
